Review

rabbit anti human siglec 9 (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech rabbit anti human siglec 9

CCRT Induces Upregulation of Siglec-10 <t>and</t> <t>Siglec-9</t> in Macrophages and Promotes M2 Polarization A Gene expression feature plots for the expression of Siglec-10. B Violin plots for the expression of Siglec-10 in CCRT and TN groups. C Gene expression feature plots for the expression of Siglec-9. D Violin plots for the expression of Siglec-9 in CCRT and TN groups. E Circos plot for the potential interactions among ten major cell types via CD24 and Siglec-10 predicted by CellChat. F Circos plot for the potential interactions among ten major cell types via MUC16 and Siglec-9 predicted by CellChat. G UMAP plots for the cell distribution in the macrophage subgroup analysis. H UMAP plots for macrophages from TN and CCRT groups. I Distribution of macrophage subpopulations in CCRT and TN groups. J–K Violin plots for the expression of Siglec-10 (J) and Siglec-9 (K) in macrophages subpopulation analysis of CCRT and TN groups. L-O Flow cytometry for the expression levels of Siglec-10 (L-M) and Siglec-9 (N–O)in macrophages from cervical cancer tissues before and after CCRT. For (B), (D), (J), (K), (M) and (O), data are presented as mean ± SEM. Paired two-tailed t tests were performed. * p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; UMAP, Uniform Manifold Approximation and Projection; TN, treatment-naïve

Rabbit Anti Human Siglec 9, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+human+siglec+9/SIGLEC10+Fusion+Protein/pmc12972391-72-37-40
Average 94 stars, based on 1 article reviews

rabbit anti human siglec 9 - by Bioz Stars, 2026-09

94/100 stars

Images

1) Product Images from "Chemoradiotherapy facilitates siglec-10 + /siglec-9 + macrophage-mediated impairment of CD24 + /MUC16 + tumor cell elimination and enhances PD-L2 dependent immunosuppression in cervical cancer"

Journal: Cancer Immunology, Immunotherapy : CII

doi: 10.1007/s00262-026-04355-6

CCRT Induces Upregulation of Siglec-10 and Siglec-9 in Macrophages and Promotes M2 Polarization A Gene expression feature plots for the expression of Siglec-10. B Violin plots for the expression of Siglec-10 in CCRT and TN groups. C Gene expression feature plots for the expression of Siglec-9. D Violin plots for the expression of Siglec-9 in CCRT and TN groups. E Circos plot for the potential interactions among ten major cell types via CD24 and Siglec-10 predicted by CellChat. F Circos plot for the potential interactions among ten major cell types via MUC16 and Siglec-9 predicted by CellChat. G UMAP plots for the cell distribution in the macrophage subgroup analysis. H UMAP plots for macrophages from TN and CCRT groups. I Distribution of macrophage subpopulations in CCRT and TN groups. J–K Violin plots for the expression of Siglec-10 (J) and Siglec-9 (K) in macrophages subpopulation analysis of CCRT and TN groups. L-O Flow cytometry for the expression levels of Siglec-10 (L-M) and Siglec-9 (N–O)in macrophages from cervical cancer tissues before and after CCRT. For (B), (D), (J), (K), (M) and (O), data are presented as mean ± SEM. Paired two-tailed t tests were performed. * p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; UMAP, Uniform Manifold Approximation and Projection; TN, treatment-naïve

Figure Legend Snippet: CCRT Induces Upregulation of Siglec-10 and Siglec-9 in Macrophages and Promotes M2 Polarization A Gene expression feature plots for the expression of Siglec-10. B Violin plots for the expression of Siglec-10 in CCRT and TN groups. C Gene expression feature plots for the expression of Siglec-9. D Violin plots for the expression of Siglec-9 in CCRT and TN groups. E Circos plot for the potential interactions among ten major cell types via CD24 and Siglec-10 predicted by CellChat. F Circos plot for the potential interactions among ten major cell types via MUC16 and Siglec-9 predicted by CellChat. G UMAP plots for the cell distribution in the macrophage subgroup analysis. H UMAP plots for macrophages from TN and CCRT groups. I Distribution of macrophage subpopulations in CCRT and TN groups. J–K Violin plots for the expression of Siglec-10 (J) and Siglec-9 (K) in macrophages subpopulation analysis of CCRT and TN groups. L-O Flow cytometry for the expression levels of Siglec-10 (L-M) and Siglec-9 (N–O)in macrophages from cervical cancer tissues before and after CCRT. For (B), (D), (J), (K), (M) and (O), data are presented as mean ± SEM. Paired two-tailed t tests were performed. * p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; UMAP, Uniform Manifold Approximation and Projection; TN, treatment-naïve

Techniques Used: Gene Expression, Expressing, Flow Cytometry, Two Tailed Test

IL-4 Stimulation Increases PD-L2 Expression in Siglec-10 + /Siglec-9 + Macrophages A The proportions of Siglec-10 + macrophage, Siglec-9 + macrophage, Siglec-10 + /Siglec-9 + macrophage and Siglec-10 − Siglec-9 − Macrophage in the CCRT and TN groups. B Volcano plots for the differential gene expression between Siglec-10 + /Siglec-9 + macrophage and Siglec-10 − /Siglec-9 − macrophage. C GSEA for the PD-L2 pathway of Siglec-10 + /Siglec-9 + macrophage relative to Siglec-10 + /Siglec-9 + macrophage. D Boxplots for IL-4 expression levels in different cell phenotypes in CCRT and TN. E Boxplots for GATA3 expression levels in T cells in CCRT and TN. F–H Macrophages were treated with IL-4 (F), and flow cytometry (G, H) was used to detect PD-L2 expression in macrophages. I-J Flow cytometry was used to assess the expression of Siglec-10 (I) and Siglec-9 (J) in macrophages from the IL-4 treated and untreated groups.For (A), (D) and (E), data are mean ± SEM. Paired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001.For (H), (I) and (J), data are presented as mean ± SEM. Unpaired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; TN, treatment-naïve; GSEA, Gene Set Enrichment Analysis

Figure Legend Snippet: IL-4 Stimulation Increases PD-L2 Expression in Siglec-10 + /Siglec-9 + Macrophages A The proportions of Siglec-10 + macrophage, Siglec-9 + macrophage, Siglec-10 + /Siglec-9 + macrophage and Siglec-10 − Siglec-9 − Macrophage in the CCRT and TN groups. B Volcano plots for the differential gene expression between Siglec-10 + /Siglec-9 + macrophage and Siglec-10 − /Siglec-9 − macrophage. C GSEA for the PD-L2 pathway of Siglec-10 + /Siglec-9 + macrophage relative to Siglec-10 + /Siglec-9 + macrophage. D Boxplots for IL-4 expression levels in different cell phenotypes in CCRT and TN. E Boxplots for GATA3 expression levels in T cells in CCRT and TN. F–H Macrophages were treated with IL-4 (F), and flow cytometry (G, H) was used to detect PD-L2 expression in macrophages. I-J Flow cytometry was used to assess the expression of Siglec-10 (I) and Siglec-9 (J) in macrophages from the IL-4 treated and untreated groups.For (A), (D) and (E), data are mean ± SEM. Paired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001.For (H), (I) and (J), data are presented as mean ± SEM. Unpaired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; TN, treatment-naïve; GSEA, Gene Set Enrichment Analysis

Techniques Used: Expressing, Gene Expression, Flow Cytometry, Two Tailed Test

M2-like Macrophages Suppress T Cell Function via PD-L2 Following CCRT A UMAP plots for the cell distribution in macrophages and CD8 + T cells subgroup analysis. B Dotplot for marker genes of different cell types of the scRNA-seq data. C Distribution of macrophages and CD8 + T cells subpopulations in CCRT and TN groups of patients with cervical cancer. D Violin plots for the expression of PD-L2 in CCRT and TN in macrophage subpopulations. E Violin plots for the expression of PDCD1 in CCRT and TN in CD8 + T cells subpopulations. F–G Flow cytometry for the expression levels of PD-L2 in macrophages from cervical cancer tissues before and after CCRT. H–I Flow cytometry for the expression levels of PD-1 in T cells from cervical cancer tissues before and after CCRT. J Circos plot for the potential interactions among Siglec-10 + macrophages and T cells via PD-L2 and PD-1 predicted by CellChat. K Circos plot for the potential interactions among Siglec-9 + macrophages and T cells via PD-L2 and PD-1 predicted by CellChat. For (D) (E), (G) and (I), data are presented as mean ± SEM. Paired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; UMAP, Uniform Manifold Approximation and Projection; scRNA-seq, single-cell RNA sequencing; TN, treatment-naïve

Figure Legend Snippet: M2-like Macrophages Suppress T Cell Function via PD-L2 Following CCRT A UMAP plots for the cell distribution in macrophages and CD8 + T cells subgroup analysis. B Dotplot for marker genes of different cell types of the scRNA-seq data. C Distribution of macrophages and CD8 + T cells subpopulations in CCRT and TN groups of patients with cervical cancer. D Violin plots for the expression of PD-L2 in CCRT and TN in macrophage subpopulations. E Violin plots for the expression of PDCD1 in CCRT and TN in CD8 + T cells subpopulations. F–G Flow cytometry for the expression levels of PD-L2 in macrophages from cervical cancer tissues before and after CCRT. H–I Flow cytometry for the expression levels of PD-1 in T cells from cervical cancer tissues before and after CCRT. J Circos plot for the potential interactions among Siglec-10 + macrophages and T cells via PD-L2 and PD-1 predicted by CellChat. K Circos plot for the potential interactions among Siglec-9 + macrophages and T cells via PD-L2 and PD-1 predicted by CellChat. For (D) (E), (G) and (I), data are presented as mean ± SEM. Paired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; UMAP, Uniform Manifold Approximation and Projection; scRNA-seq, single-cell RNA sequencing; TN, treatment-naïve

Techniques Used: Cell Function Assay, Marker, Expressing, Flow Cytometry, Two Tailed Test, Single Cell, RNA Sequencing

Incubation:

Article Title: Chemoradiotherapy facilitates siglec-10 + /siglec-9 + macrophage-mediated impairment of CD24 + /MUC16 + tumor cell elimination and enhances PD-L2 dependent immunosuppression in cervical cancer
Article Snippet: .. Subsequently, the sections were blocked with antibody diluent (Dako) for 1 h, followed by incubation overnight at 4 °C with the following primary antibodies: mouse anti-human CD68 (Invitrogen, MA5-13324, 1:100), anti-human Siglec-10-APC (Biolegend, clone 5G6, AB_11203899, 1:100), rabbit anti-human Siglec-9 (Proteintech, 1:5000), anti-human CD24-BV421 (Biolegend, clone ML5, AB_10915556, 1:200), and anti-human MUC16-Alexa Fluor 594 (R&D SYSTEMS, FAB56091T, 1:200). .. After washing, the sections were stained for 1 h with secondary antibodies: goat anti-mouse Alexa Fluor 488 (Invitrogen, A-11029, 1:800) and goat anti-rabbit Cyanine5 (Invitrogen, A10523, 1:500).

Image Search Results

Journal: Cancer Immunology, Immunotherapy : CII

doi: 10.1007/s00262-026-04355-6

Figure Lengend Snippet: CCRT Induces Upregulation of Siglec-10 and Siglec-9 in Macrophages and Promotes M2 Polarization A Gene expression feature plots for the expression of Siglec-10. B Violin plots for the expression of Siglec-10 in CCRT and TN groups. C Gene expression feature plots for the expression of Siglec-9. D Violin plots for the expression of Siglec-9 in CCRT and TN groups. E Circos plot for the potential interactions among ten major cell types via CD24 and Siglec-10 predicted by CellChat. F Circos plot for the potential interactions among ten major cell types via MUC16 and Siglec-9 predicted by CellChat. G UMAP plots for the cell distribution in the macrophage subgroup analysis. H UMAP plots for macrophages from TN and CCRT groups. I Distribution of macrophage subpopulations in CCRT and TN groups. J–K Violin plots for the expression of Siglec-10 (J) and Siglec-9 (K) in macrophages subpopulation analysis of CCRT and TN groups. L-O Flow cytometry for the expression levels of Siglec-10 (L-M) and Siglec-9 (N–O)in macrophages from cervical cancer tissues before and after CCRT. For (B), (D), (J), (K), (M) and (O), data are presented as mean ± SEM. Paired two-tailed t tests were performed. * p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; UMAP, Uniform Manifold Approximation and Projection; TN, treatment-naïve

Article Snippet: Subsequently, the sections were blocked with antibody diluent (Dako) for 1 h, followed by incubation overnight at 4 °C with the following primary antibodies: mouse anti-human CD68 (Invitrogen, MA5-13324, 1:100), anti-human Siglec-10-APC (Biolegend, clone 5G6, AB_11203899, 1:100), rabbit anti-human Siglec-9 (Proteintech, 1:5000), anti-human CD24-BV421 (Biolegend, clone ML5, AB_10915556, 1:200), and anti-human MUC16-Alexa Fluor 594 (R&D SYSTEMS, FAB56091T, 1:200).

Techniques: Gene Expression, Expressing, Flow Cytometry, Two Tailed Test

Journal: Cancer Immunology, Immunotherapy : CII

doi: 10.1007/s00262-026-04355-6

Figure Lengend Snippet: IL-4 Stimulation Increases PD-L2 Expression in Siglec-10 + /Siglec-9 + Macrophages A The proportions of Siglec-10 + macrophage, Siglec-9 + macrophage, Siglec-10 + /Siglec-9 + macrophage and Siglec-10 − Siglec-9 − Macrophage in the CCRT and TN groups. B Volcano plots for the differential gene expression between Siglec-10 + /Siglec-9 + macrophage and Siglec-10 − /Siglec-9 − macrophage. C GSEA for the PD-L2 pathway of Siglec-10 + /Siglec-9 + macrophage relative to Siglec-10 + /Siglec-9 + macrophage. D Boxplots for IL-4 expression levels in different cell phenotypes in CCRT and TN. E Boxplots for GATA3 expression levels in T cells in CCRT and TN. F–H Macrophages were treated with IL-4 (F), and flow cytometry (G, H) was used to detect PD-L2 expression in macrophages. I-J Flow cytometry was used to assess the expression of Siglec-10 (I) and Siglec-9 (J) in macrophages from the IL-4 treated and untreated groups.For (A), (D) and (E), data are mean ± SEM. Paired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001.For (H), (I) and (J), data are presented as mean ± SEM. Unpaired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; TN, treatment-naïve; GSEA, Gene Set Enrichment Analysis

Techniques: Expressing, Gene Expression, Flow Cytometry, Two Tailed Test

Journal: Cancer Immunology, Immunotherapy : CII

doi: 10.1007/s00262-026-04355-6

Figure Lengend Snippet: M2-like Macrophages Suppress T Cell Function via PD-L2 Following CCRT A UMAP plots for the cell distribution in macrophages and CD8 + T cells subgroup analysis. B Dotplot for marker genes of different cell types of the scRNA-seq data. C Distribution of macrophages and CD8 + T cells subpopulations in CCRT and TN groups of patients with cervical cancer. D Violin plots for the expression of PD-L2 in CCRT and TN in macrophage subpopulations. E Violin plots for the expression of PDCD1 in CCRT and TN in CD8 + T cells subpopulations. F–G Flow cytometry for the expression levels of PD-L2 in macrophages from cervical cancer tissues before and after CCRT. H–I Flow cytometry for the expression levels of PD-1 in T cells from cervical cancer tissues before and after CCRT. J Circos plot for the potential interactions among Siglec-10 + macrophages and T cells via PD-L2 and PD-1 predicted by CellChat. K Circos plot for the potential interactions among Siglec-9 + macrophages and T cells via PD-L2 and PD-1 predicted by CellChat. For (D) (E), (G) and (I), data are presented as mean ± SEM. Paired two-tailed t tests were performed.* p < 0.05,** p < 0.01,*** p < 0.001,**** p < 0.0001. CCRT, concurrent chemoradiotherapy; UMAP, Uniform Manifold Approximation and Projection; scRNA-seq, single-cell RNA sequencing; TN, treatment-naïve

Techniques: Cell Function Assay, Marker, Expressing, Flow Cytometry, Two Tailed Test, Single Cell, RNA Sequencing

Review

rabbit anti human siglec 9 (Proteintech)

Structured Review

Images

1) Product Images from "Chemoradiotherapy facilitates siglec-10 + /siglec-9 + macrophage-mediated impairment of CD24 + /MUC16 + tumor cell elimination and enhances PD-L2 dependent immunosuppression in cervical cancer"

Related Articles

Incubation:

Similar Products

Image Search Results